c Dosing may be modified to as low as 1.25 ng/kg/min for those patients considered ie, MAP remains “hyper-responders”, 85 mmHg despite discontinuation of vasopressin and all catecholamines. ≥ Supplemental Table 4. Titration schema: hour 3 through hour 48 (nonbinding) Study Drug Titration Study Drug Maximal Study Drug Minimal Current MAP Interval Study Drug Dose Titration Dose Dose mmHg min ng/kg/min ng/kg/min ng/kg/min 59 5 Increase to 40 40 2.5 ≤ 60-64 15 Increase by 10 40 2.5 65-70 15 Maintain dose a 40 2.5 70 15 Decrease by 10 b 40 2.5 c ≥ MAP=mean arterial pressure. a If the sum of the norepinephrine + epinephrine dose is 0.03 but < 0.1 µg/kg/min, study drug dose should be maintained. ≥ b If vasopressin is being used, vasopressin should be weaned off first. Then, titrate standard-of-care vasopressors until the sum of the norepinephrine + epinephrine dose is as low as 0.03 µg/kg/min. c Dosing may be modified to as low as 1.25 ng/kg/min for those patients considered ie, MAP remains “hyper-responders”, 70 mmHg despite discontinuation of vasopressin and reduction of sum norepinephrine + epinephrine dose to as low as ≥ 0.03 µg/kg/min.
c Dosing may be modified to as low as 1.25 ng/kg/min for those patients considered “hyper-responders”, ie, MAP remains ≥ 85 mmHg despite discontinuation of vasopressin and all catecholamines. Supplemental Table 4. Titration schema: hour 3 through hour 48 (nonbinding) Current MAP mmHg Study Drug Titration Interval min Study Drug Dose Titration ng/kg/min Study Drug Maximal Dose ng/kg/min Study Drug Minimal Dose ng/kg/min ≤ 59 5 Increase to 40 40 2.5 60-64 15 Increase by 10 40 2.5 65-70 15 Maintain dose a 40 2.5 ≥ 70 15 Decrease by 10 b 40 2.5 c MAP=mean arterial pressure. a If the sum of the norepinephrine + epinephrine dose is ≥ 0.03 but < 0.1 µg/kg/min, study drug dose should be maintained. b If vasopressin is being used, vasopressin should be weaned off first. Then, titrate standard-of-care vasopressors until the sum of the norepinephrine + epinephrine dose is as low as 0.03 µg/kg/min. c Dosing may be modified to as low as 1.25 ng/kg/min for those patients considered “hyper-responders”, ie, MAP remains ≥ 70 mmHg despite discontinuation of vasopressin and reduction of sum norepinephrine + epinephrine dose to as low as 0.03 µg/kg/min.
CCM_46_6_2018_02_23_TUMLIN_CCMED-D-18-00159_SDC1.docx